Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trofinetide in girls 2-5 years with Rett syndrome
NCT04988867Phase 3Terminated
- Sponsor
- Acadia Pharmaceuticals
- Start
- Sep 2021
- Primary completion
- May 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of trofinetide in Rett syndrome (RTT), sponsored by Acadia Pharmaceuticals. Primary endpoints: Safety and Tolerability of Treatment With Oral Trofinetide at 434 days, Area Under the Concentration-time Curve From Time 0 to 12 h at Steady State and 3 more. Started Sep 2021; status: terminated.
02
Drugs
trofinetide
03
Conditions
Rett syndrome (RTT)
Beyond the preview
Go deeper on NCT04988867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04988867.